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ABSTRACT 
Background. Sarcopenia is common among older hospitalized adults but estimates vary according 
to definitions used. Aims of this study were to investigate the agreement between the European 
Working Group on Sarcopenia in Older People (EWGSOP2) and the Foundation for the National 
Institutes of Health (FNIH) Sarcopenia Project criteria and to compare the predictive value of both 
definitions for 3-year mortality.  
 
Methods. Analysis was performed on 610 older hospitalized patients enrolled in the GLISTEN 
study. Participants were categorized as sarcopenic or not sarcopenic according to EWGSOP2 and 
FNIH definitions separately and in a four-group variable (neither criterion positive, only 
EWGSOP2, only FNIH, both criteria).  
 
Results. Sarcopenia prevalence was 22.8% and 23.9% using EWGSOP2 and FNIH criteria 
respectively, with a low classification agreement (Cohen’s kappa statistic: 0.29). Sarcopenic 
participants by each definitions had higher mortality rate when compared to those not sarcopenic 
(both log-rank test: p<0.001). Participants that met both positive criteria had the shorter survival as 
compared with the other three groups. Cox models showed that, after adjustment for potential 
confounders, only EWGSOP2 definition predicted 3-years mortality (HR 1.84; 95%C.I. 1.33-2.57). 
When the four-group variable was used, compared with the NO EWGSOP2/NO FNIH group, 
significant mortality risk was found for the EWGSOP2 (HR 2.08; 95%C.I. 1.38-3.16) and the 
combined EWGSOP2/FNIH group (HR 1.75; 95%C.I. 1.11-2.79). 
 
Conclusions. Agreement between EWGSOP2 and FNIH definitions is poor. Sarcopenia on hospital 
admission is associated with increased risk of 3-year mortality and EWGSOP2 criteria seem to have 
the highest predictive value. 
Key words: Sarcopenia, hospital, acute care, mortality 
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INTRODUCTION 
 
The aging process is characterized by a progressive decline in skeletal muscle mass, resulting in 
loss of muscle strength and function, condition that has been referred to as sarcopenia (1). 
Sarcopenia is receiving an increasing interest in research and practice (2) due to its high prevalence, 
especially in nursing home or hospital setting (3), and its association with mobility impairment, 
disability, loss of independence, poor quality of life, hospitalization, and death (4). Furthermore, 
sarcopenia has been recently recognized as a specific disease entity, deserving its own ICD-10-CM 
code (M62.84) (5).  
However, one of the major obstacles in both research and clinical practice is the lack of consensus 
regarding the diagnostic criteria and the methods used to assess such a condition. The most widely 
used definitions of sarcopenia are those proposed by the European Working Group on Sarcopenia in 
Older People (EWGSOP) (6) and the Foundation for the National Institutes of Health (FNIH) 
Sarcopenia Project (7). Despite handgrip strength and skeletal muscle mass are key features in all 
sarcopenia definitions, cut off values and techniques used to assess muscle mass and strength differ 
between definitions, resulting in a low concordance between FNIH and EWGSOP criteria (8) and, 
specifically, in a low positive percent agreement (PPA) where PPA was defined by Dam et al. as the 
proportion of participants who were categorized as having sarcopenia by both the FNIH criteria and 
EWGSOP divided by the number of participants who were categorized as having the condition by 
the second set of criteria (9). Recently, the European Working Group updated the original definition 
in order to incorporate the new insights collected on the condition over the last decade, and 
proposed a new operational definition of sarcopenia, the EWGSOP2 (10).  
So far, no data are available on the agreement between the new EWGSOP2 and the FNIH 
sarcopenia definitions. Moreover, it is unclear whether the different sarcopenia definitions have 
similar associations with clinical outcomes, such as mortality. The primary objective of this report 
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was to investigate the agreement between EWGSOP2 and FNIH sarcopenia definitions in a sample 
of older patients admitted to 12 Geriatrics and Internal Medicine acute care wards in Italy, enrolled 
in the GLISTEN Study (11). Furthermore, we sought to compare the predictive value of both 
definitions towards 3-year mortality.  
METHODS 
 
Study Design and Data Collection 
 
Data were obtained from the Gruppo di Lavoro Italiano Sarcopenia – Trattamento E Nutrizione 
(GLISTEN) project, a cohort study performed in Geriatric and Internal Medicine acute care wards 
of 12 Italian hospitals (Monza, Turin, Ferrara, Verona, Parma, Florence, Ancona, Rome, Napoli I, 
Napoli II, Cagliari, Messina). Methodology of the GLISTEN project has been described in detail 
elsewhere (11). Briefly, the study was designed to investigate the prevalence and clinical correlates 
of sarcopenia in older hospitalized patients in Italy and to estimate the incidence of sarcopenia 
during hospital stay. All study centers obtained ethical approval from their institutions; participants 
signed a written informed consent. All patients consecutively admitted to the participating wards 
from February 2014 and May 2014 were screened for enrollment. Exclusion criteria were age 
younger than 65 years and patient’s unwillingness to take part in the study. All patients were 
assessed within 2 days since hospital admission and were followed until discharge. Participants’ 
data were collected through a standardized dedicated questionnaire including demographic 
characteristics, self-report functional status, cognitive, and mood assessment; medication use; 
incident and prevalent medical conditions; and biochemical test results. Objective measures of 
muscle mass (bioimpedance analysis [BIA]) and physical performance (handgrip strength and 4-m 
usual walking speed) were obtained at hospital admission and before discharge. Survival status was 
recorded up to 36 months after hospital discharge. In this study, 45 of the original 655 enrollees 
were excluded because of some baseline missing data, leading to a final sample of 610 persons 
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(mean age 80.7 ± 6.6 years, male 48.7%). Mortality data were available in 527 participants, who 
were therefore included in survival analyses.  
 
Assessment of Sarcopenia 
 
According to EWGSOP2 (10) and FNIH criteria (12), sarcopenia was defined as presence of low 
muscle strength plus low muscle mass assessed at hospital admission.  
Muscle strength was assessed by grip strength (GS), measured using a calibrated hand-held 
dynamometer (JAMAR hand dynamometer Model BK-7498, Fred Sammons Inc., Brookfield, IL). 
According to Southampton protocol (13), three trials for each hand were performed in sitting or 
supine position (14), and the highest value of the strongest hand was used in the analyses. GS 
values below 27 kg in men and 16 kg in women were considered as abnormal according to the 
EWGSOP2 consensus (15). The corresponding cut-offs for the FNIH criteria were 26 kg and 16 kg 
for men and women, respectively (16).  
 
Muscle mass was measured by BIA using a Quantum/S Bioelectrical Body Composition Analyzer 
(Akern Srl, Florence, Italy). Whole-body BIA measurements were taken with standard four‐pole 
technique between the right wrist and ankle with the subject in a supine position using a sinusoidal 
current at 50 kHz frequency. Appendicular Skeletal muscle Mass (ASM) was calculated using the 
following equation by Sergi and colleagues (17): ASM (Kg)= -3.964 + (0.227 x height2/resistance) 
+ (0.095 x weight)+ (1.384 x sex) + (0.064 x reactance) where height is measured in centimeters, 
resistance and reactance in ohms, weight in kilograms; for gender, men=1 and women=0. ASM was 
standardized by height squared (ASM/height2) and Body Mass Index (ASM/BMI) as requested by 
EWGSOP2 and FNIH criteria, respectively. Low appendicular muscle mass was classified as 
ASM/height2 less than 7.0 kg/m2 in men and 5.5 kg/m2 in women, in line with EWGSOP2 cut-off 
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points (18), and as a ASM/BMI ratio lower than 0.789 in men and 0.512 and women, according to 
FNIH (19). 
 
Covariates 
Sociodemographic variables (age, gender, smoking habits, education) were obtained through 
clinical interview at hospital admission. Cognitive functioning and functional status in six basic 
activities of daily living (ADL) were assessed as reported elsewhere (11). Severe ADL disability 
was defined as the presence of difficulty in three or more activities (20). Cognitive functioning was 
assessed using the Short Portable Mental Status Questionnaire (SPMSQ). The total number of 
errors on individual test’s items was added to provide the SPMSQ score (one or two errors indicate 
normal cognitive status; 3–4 errors indicate mild; 5–7 errors indicate moderate; and 8–10 errors 
indicate severe cognitive impairment) (21). Diagnoses of specific medical conditions were gathered 
from the participant, the attending physicians, and medical charts review; comorbidity was assessed 
using the Charlson Comorbidity Index (22) by adding scores assigned to specific diagnoses. 
Assessors recorded all drugs currently taken by the participants on admission; number of drugs 
taken was also calculated. 
 
 
Mortality 
Mortality data of the original GLISTEN cohort were collected using data from the Mortality 
General Registry maintained by each Region. Time from the day of study enrollment to last follow 
up (date of death or April 26, 2017) was considered as temporal function in our study. No 
information on cause of death were collected. 
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Statistical analysis 
Prevalence of sarcopenia was assessed using each algorithm; concordance between the two 
definitions was visually assessed with a mosaic plot of frequencies and quantitatively evaluated 
with Cohen’s kappa coefficients. Kappa values, that is a measure of agreement corrected to take 
into account the amount of concordance due to chance, varies between 0 and 1 and can be 
interpreted as follows: 0-0.39 indicating minimal agreement, 0.40–0.59 as weak, 0.60– 0.79 as 
moderate, ≥0.80 as strong agreement (23)  
A combination definition was also considered (neither criterion positive, only EWGSOP2 criterion 
positive, only FNIH criterion positive, both criteria). 
Baseline characteristics were compared across the sarcopenia groups. Continuous variables 
distribution was visually inspected through histograms and normal qq-plot. Continuous data with 
approximately normal distribution were described as mean ± standard deviation and compared by t-
test and one-way ANOVA. Median [interquartile range, IQR] and, accordingly, the Mann–Whitney 
U and Kruskal–Wallis tests, were used when the distribution deviated substantially from normal. 
Categorical variables were summarized in terms of percentages and were compared by using the 
Pearson’s chi squared test or the Fisher’s exact test, as appropriate. 
Crude mortality rates were estimated, and Kaplan-Meier curves were fitted to explore survival 
probabilities. The log-rank test and Cox regression analysis were used to assess the effect of 
sarcopenia on 3-year mortality. Three Cox models were hierarchically fitted: unadjusted, age and 
gender adjusted, and adjusted for other potential confounders (i.e. age, gender, SPMSQ, severe 
ADL disability, Charlson Comorbidity Index). 
All analyses were done using Stata version 13 (StataCorp, College Station, TX) and statistical 
significance was set at 0.05.
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RESULTS  
Participants’ baseline characteristics  
One hundred thirty-nine participants (22.8%) and 146 (23.9%) met EWGSOP2 and FNIH criteria, 
respectively. Baseline characteristics of participants according to the presence of sarcopenia, 
defined by each criterion separately, are presented in Table 1. Compared with participants without 
sarcopenia, those diagnosed with sarcopenia according to EWGSOP2 definition were significantly 
older (p< 0.001), had lower BMI (p< 0.001), greater prevalence of weight loss in the previous 6 
months (p<0.001) and severe ADL disability (p= 0.032). Using FNIH definition, no significant age 
difference was found between sarcopenic and the non-sarcopenic counterpart; sarcopenic 
participants had higher BMI (p< 0.001), greater prevalence of severe ADL disability (p< 0.001), 
diabetes (p= 0.030), chronic obstructive pulmonary disease (p= 0.004), higher number of errors at 
SPSMQ test (p= 0.024), higher Charlson Index score (p= 0.031) and a greater number of 
medications (p= 0.045). 
 
Agreement between EWGSOP2 and FNIH definitions  
Figure 1 shows agreement between the 2 sarcopenia definitions: out of the 220 participants who 
were classified as sarcopenic by at least one definition, agreement was obtained in only 65 (10.7%), 
whereas 12.1% were classified as sarcopenic by EWGSOP2 but not FNIH criterion and 13.3% as 
sarcopenic by FNIH but not EWGSOP2 criterion. Cohen’s kappa coefficient was 0.29.  
Compared to those deemed as non-sarcopenic by both definitions and those identified as sarcopenic 
by one but not the other, participants with agreement sarcopenia status were older, had greater 
prevalence of male, smokers and severe ADL disability (Table 2).  
 
Predictive value of EWGSOP2 and FNIH definitions 
During a median follow-up time of 30.1 months, 178 participants (33.8% of the 527 in whom 
survival status could be ascertained) died. As shown in Figures 2, participants with sarcopenia by 
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EWGSOP2 (2a) and FNIH (2b) definitions had higher mortality rate when compared with those 
without sarcopenia (log-rank test: p<0.001 for both definitions). Participants with agreement on 
sarcopenia status (Figure 2c) had the shorter survival as compared with the other three groups.  
Estimates derived from the Cox proportional hazard models (Table 3) showed that sarcopenic 
participants, regardless of the definition used, were more likely to die compared to non-sarcopenic 
individuals (model 1); nevertheless, after adjusting for potential confounders (model 3), the results 
were confirmed only for EWGSOP2 sarcopenic participants (HR 1.84; 95% C.I. 1.33-2.57). 
Furthermore, when the four-grouping variable was used, a similar significant mortality risk was 
found for the EWGSOP2 group and for the combined EWGSOP2/FNIH group (HR 2.08; 95% C.I. 
1.38-3.16) and HR 1.75; 95% C.I. 1.11-2.79 respectively) compared to the NO EWGSOP2/NO 
FNIH group. 
  
DISCUSSION 
This study, performed in a cohort of older patients admitted to Geriatric and Internal Medicine acute 
care wards, showed that agreement between EWGSOP2 and FNIH definitions on the identification 
of sarcopenic patients is poor, therefore the two definitions cannot be used interchangeably. Both 
sarcopenia definitions were associated with increased 3-year mortality, although the EWGSOP2 
seemed to have the best predictive value in terms of mortality.  
 
Agreement between EWGSOP2 and FNIH definitions  
Previous reports in which the original EWGSOP was compared to FNIH sarcopenia definition 
showed that the prevalence of such condition varied substantially when different diagnostic criteria 
were used (8, 9, 24). Agreement was not improved in our study, where sarcopenia prevalence was 
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similar among EWGSOP2 and FNIH definitions but, more importantly, the overlap between the 
two definitions was low (kappa statistics = 0.29).  
EWGSOP2 and FNIH definitions have similar conceptual frameworks and both include measures of 
lean mass and strength. As previously explained by Dam and Colleagues (9), we believe that the 
lack of agreement between these two criteria is mainly explained by differences in the 
categorization of low muscle mass. On one hand, EWGSOP2 criteria recommend the utilization of 
ASM adjusted for height or ASM (12), on the other, FNIH criteria recommend to use ASM adjusted 
for BMI as first choice (10). As a result of that categorization, subjects identified as sarcopenic by 
EWGSOP2 criteria in the present study had lower average BMI, no case of obesity, higher 
prevalence of underweight (23.7%, data not shown), and higher rates of reported weight loss in the 
last 6 months, compared to those identified with FNIH criteria. Conversely, sarcopenic patients 
according to FNIH definition were characterized by high prevalence of obesity (31%, data not 
shown) and diabetes, with a negligible prevalence of underweight (2.7%, data not shown). As 
already commented, FNIH criteria seems to identify participants that, despite having high lean mass 
and high BMI, are functionally more impaired because are unable to generate enough muscular 
strength relative to their body mass (condition conceptualized as sarcopenic obesity) (9). 
EWGSOP2, as well as EWGSOP criteria, instead, seem to catch malnourished patients and, 
possibly, might include cachectic patients as previously investigated in the same sample (11).  
 
Predictive value of EWGSOP2 and FNIH definitions 
Previous prospective studies have evaluated the validity of the original EWGSOP and FNIH criteria 
for predicting mortality in several settings (4, 25-27), including acute care wards (24, 28). Only one 
recent report, instead, has examined the predictive value of the new EWGSOP2 sarcopenia 
definition in terms of mortality in a group of community-dwelling older persons (29). In all these 
cohorts, sarcopenia was associated with a high risk of all-cause mortality. Our study confirmed the 
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association between FNIH sarcopenia definition and mortality, and, for the first time, recognized 
the predictive value of the EWGSOP2 criteria applied in a hospital setting.  
Cox regression analyses showed that sarcopenia, according to both definitions, represents an 
independent risk factor for mortality, even though statistical significance was reduced for FNIH 
definition after adjusting for comorbidity, cognitive status and disability. Furthermore, when the 
two definitions were combined, generating a four-group variable, only EWGSOP2 and 
EWGSOP2/FNIH combined group showed a significant independent risk of mortality. Although 
generalization of these findings should obviously be done with caution given the relatively small 
number of patients, our results suggest that EWGSOP2 might predict mortality better than FNIH 
definition in acutely hospitalized sarcopenic patients. However, the main finding that should be 
highlighted is that using each definition, we lost a share of sarcopenic subjects that are at increased 
risk mortality.  
 
Clinical research has to progress in order to overcoming the discrepancy between sarcopenia 
definitions, and our study strongly supports the need not only of reaching general consensus in the 
criteria and cut-off values for sarcopenia to enable a comparison between studies, but, above all, to 
identify all the individuals at risk of complication related to sarcopenia.  
 
Strength and limitations  
Our study has several strengths. It is a large, multicenter, prospective cohort study involving 
Geriatric and Internal Medicine hospital units, thus providing easily generalizable information from 
the “real-world”. Second, we explored the association between sarcopenia and mortality, which has 
been rarely investigated in a hospital setting. Third, this is the first study that investigated the 
predictive value of EWGSOP2 sarcopenia definition and compared EWGSOP2 and FNIH criteria in 
a hospital setting: thus, our results are of current interest for researchers and major relevance for 
clinicians. 
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Nevertheless, in interpreting these findings, some limitations should be considered. First, we 
estimated appendicular muscle mass by BIA using Sergi equation instead of dual energy X-ray 
absorptiometry (DEXA), the technique that is recognized as the gold standard for the assessment of 
muscle mass. BIA measures are affected by the hydration status of patients, which admittedly 
change very rapidly in geriatric patients; nevertheless, this technique is inexpensive, easy to use, 
readily reproducible, and appropriate for bedridden patients, being therefore considered as an 
acceptable alternative to DEXA in a hospital setting (30).  
Second, as previously described (11), the assessment of sarcopenia in acutely ill older patients 
might be affect by a transient impairment in muscle strength, unrelated to sarcopenia, but due to the 
systemic effect of the acute disease responsible for hospital admission, leading to a potential 
overestimation of the condition. Third, we cannot exclude that the association between sarcopenia 
and mortality is related to residual confounding, because data on some potential confounders 
(including admission diagnoses) were not collected. Fourth, this study was conducted on a cohort of 
hospitalized older people, therefore generalization of results to community dwelling or 
institutionalized older people is not possible. In this regard, further researches are needed to confirm 
the association between the two sarcopenia’s phenotypes and mortality in these populations. 
Finally, the evaluation of the prognostic utility of sarcopenia definition should include additional 
important clinical endpoints, including functional status and disability, not assessed in our work. 
 
In summary, in this sample of Italian hospitalized geriatric patients, the agreement between 
EWGSOP2 and FNIH definitions was low, suggesting that these criteria cannot be used 
interchangeably. Diagnosis of sarcopenia on hospital admission was associated with increased risk 
of 3-year mortality and EWGSOP2 criteria seemed to have the best predictive value in terms of 
mortality. Future research is needed to examine consistency of sarcopenia definitions and their 
clinical implications, and to overcome the discrepancy between current diagnostic criteria, in order 
to identify all the individuals at risk for complications related to sarcopenia. 
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Table 1. Selected general characteristics of study participants according to definition and presence 
of sarcopenia 
 EWGSOP2 FNIH 
No Sarcopenia Sarcopenia p No Sarcopenia Sarcopenia p  
N (%) 471 (77.2)  139 (22.8)  464 (76.1) 146 (23.9)  
Age, mean ± SD  80.2 ± 6.5 82.4 ± 6.8 <.001 80.6 ± 6.5 80.9 ± 6.9 .627 
Male sex (%) 44.2 64.0 <.001 42.9 67.1 <.001 
BMI, mean ± SD 27.6 ± 4.9 22.5 ± 3.1 <.001 25.8 ± 4.8 28.2 ± 5.4 <.001 
Weight loss (%) 39.2 56.1 <.001 43.1 43.1 .987 
Smokers (former/current) (%) 45.5 54.0 .079 44.3 57.3 .006 
Education (years), median 
[IQR] 
5 [5, 8] 5 [5, 8] .477 5 [5, 8] 5 [5, 8] .195 
Severe ADL disability (%) 21.4 30.2 .032 20.0 34.2 <.001 
SPMSQ, median [IQR] 2 [1, 3] 2 [1, 4] .068 2 [1, 4] 2 [1, 4] .024 
Hypertension (%) 77.1 71.2 .158 75.0 78.1 .449 
Congestive heart failure (%) 16.4 19.4 .397 16.8 17.8 .780 
Coronary heart disease (%) 25.5 30.9 .206 27.2 25.3 .656 
Diabetes (%) 30.8 23.7 .108 26.9 36.3 .030 
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Notes. EWGSOP2= European Working Group on Sarcopenia in Older People 2; FNIH= Foundation 
for the National Institutes of Health; p= p-value; SD= standard deviation; BMI= Body Mass Index; 
ADL= Activities of Daily Living; SPMSQ= Short Portable Mental Status Questionnaire; IQR= 
interquartile range; COPD= chronic obstructive pulmonary disease; p-values refer to: t-test for age, 
BMI and number of drugs, Wilcoxon-Mann-Whitney for SPMSQ, education and Charlson 
Comorbidity Index, Chi-squared test for categorical variables. 
COPD, n (%) 26.5 26.6 .985 23.7 35.6 .004 
Osteoporosis, n (%) 14.9 21.6 .060 16.8 15.1 .200 
Chronic kidney disease, n (%) 21.9 23.7 .641 22.2 22.6 .918 
Charlson Comorbidity Index, 
median [IQR] 
3 [1, 5] 3 [2, 5] .517 3 [1, 4] 3 [2, 5] .031 
Number of drugs, mean ± SD  6.1 ± 2.9 6.1 ± 2.7 .837 5.9 ± 2.9 6.5 ± 2.7 .045 
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Table 2. Selected general characteristics of study participants according to four sarcopenia groups  
   
  
Sarcopenia 
  
EWGSOP2 
FNIH 
NO 
NO 
YES 
NO 
NO 
YES 
YES 
YES 
p  
N (%) 390 (63.9) 74 (12.1) 81 (13.3) 65 (10.7)  
Age, mean ± SD  80.4 ± 6.4 81.8 ± 7.0 79.2 ± 6.7 83.1 ± 6.6 .001 
Male sex (%) 40.8 54.1 60.5 75.4 <.001 
BMI, mean ± SD 26.7 ± 4.5 21.1 ± 2.8 31.6 ± 4.6 24.0 ± 2.8 <.001 
Weight loss (%) 39.7 60.8 37.0 50.8 .003 
Smokers (former/current) (%) 43.8 47.3 53.8 61.9 .034 
Education (years), median [IQR] 5 [5, 8] 5 [5, 8] 5 [4, 8] 5 [5, 8] .145 
Severe ADL disability (%) 20.0 20.3 28.4 41.5 .001 
SPMSQ, median [IQR] 2 [1, 3] 2 [1, 4] 2 [1, 4] 2 [1, 5] .082 
Hypertension (%) 75.6 71.6 84.0 70.8 .210 
Congestive heart failure (%) 16.7 17.6 14.8 21.5 .737 
Coronary heart disease (%) 25.7 35.1 24.7 26.2 .383 
Diabetes (%) 28.2 20.3 43.2 27.7 .013 
COPD, n (%) 24.4 20.3 37.0 33.9 .032 
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Osteoporosis, n (%) 15.4 24.3 12.4 18.5 .183 
Chronic kidney disease, n (%) 21.8 24.3 22.2 23.1 .968 
Charlson Comorbidity Index, median 
[IQR] 
3 [1, 4] 3 [2, 4] 3 [2, 5] 3 [1, 4] .164 
Number of drugs, mean ± SD  5.9 ± 2.9 5.9 ± 2.8 6.7 ± 2.9 6.3 ± 2.6 .198 
 
Notes. EWGSOP2= European Working Group on Sarcopenia in Older People 2; FNIH= Foundation 
for the National Institutes of Health; p= p-value; SD= standard deviation; BMI= Body Mass Index; 
ADL= Activities of Daily Living; SPMSQ= Short Portable Mental Status Questionnaire; IQR= 
interquartile range; COPD= chronic obstructive pulmonary disease; p-values refer to: ANOVA for 
age and number of drugs, Kruskal Wallis for BMI, SPMSQ, education and Charlson Comorbidity 
Index, Chi-squared test for categorical variables. 
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Table 3. Association between Each Sarcopenia definition and Mortality According to Cox 
Regression Models Adjusted for Potential Confounders 
 
Mortality Rate 
100 person-year 
Model 1 Model 2 Model 3  
 
HR  
(95% CI) 
HR  
(95% CI) 
HR  
(95% CI) 
EWGSOP2     
No sarcopenia 12.9 
1  
- 
1 
- 
1 
- 
Sarcopenia 29.9 
2.24 
(1.64-3.07) 
1.87 
(1.35-2.59) 
1.84 
(1.33-2.57) 
FNIH     
No sarcopenia 14.0 
1  
- 
1  
- 
1 
- 
Sarcopenia 23.8 
1.66 
(1.20-2.30) 
1.54 
(1.11-2.15) 
1.26 
(0.89-1.79) 
Combined sarcopenia definition     
NO EWGSOP2/ NO FNIH 11.9 
1  
- 
1 
- 
1 
- 
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YES EWGSOP2/ NO FNIH 28.5 
2.33 
(1.56-3.48) 
1.98 
(1.32-2.99) 
2.08 
(1.38-3.16) 
NO EWGSOP2/ YES FNIH 18.7 
1.55 
(1.00-2.41) 
1.56 
(1.00-2.44) 
1.25 
(0.79-1.98) 
YES EWGSOP2/ YES FNIH 31.8 
2.55 
(1.66-3.92) 
2.11 
(1.34-3.29) 
1.75 
(1.11-2.79) 
 
Notes. . EWGSOP2= European Working Group on Sarcopenia in Older People 2; FNIH= 
Foundation for the National Institutes of Health; Model 1= unadjusted; Model 2= age and gender 
adjusted; Model 3= adjusted for age, gender, Short Portable Mental Status Questionnaire, severe 
Activities of Daily Living disability, Charlson Comorbidity Index; HR= Hazard Ratio; CI= 
confidence interval 
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Figure legends 
 
Figure 1. Agreement between EWGSOP2 and FNIH definitions  
 
 
Figure 2. Kaplan-Meier survival estimates according to sarcopenia definitions 
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Figure 1 
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Figure 2 
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